Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.67 |
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987345 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29761659 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL1987346 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011266 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025643 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29527395 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011237 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011197 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025645 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| Trifluoroacetic Acid SCHEMBL31675100 | 0.94 | MME (0.60) | MMEACECPA1ACE2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| US-12208145-B2 | [161 tb]-based radiopeptides | UNIVERSITÄT BASEL (CH) | 2025-01-28 | — | — | US | claimed |
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | claimed |
| US-20240181094-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2024-06-06 | — | — | US | claimed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240123098-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2024-04-18 | — | — | US | claimed |
| WO-2024064969-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| CN-116284236-B | The method comprises the following steps of 18 F-nuclein labeled somatostatin receptor inhibitor probe, preparation method thereof and kit | 中国医学科学院北京协和医院 | 2024-02-20 | — | — | CN | claimed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230293736-A1 | [161Tb]-BASED RADIOPEPTIDES | PAUL SCHERRER INSTITUTE (CH) | 2023-09-21 | — | — | US | claimed |
| EP-4232097-A1 | [161Tb]-BASED RADIOPEPTIDES | Universität Basel (CH) | 2023-08-30 | — | — | EP | claimed |
| CN-116284236-A | The method comprises the following steps of 18 F-nuclein labeled somatostatin receptor inhibitor probe, preparation method thereof and kit | 中国医学科学院北京协和医院 | 2023-06-23 | — | — | CN | claimed |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-06-01 | — | — | US | claimed |
| WO-2023051941-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-04-06 | — | — | WO | claimed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | claimed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | claimed |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208145-B2 | [161 tb]-based radiopeptides | SSTR1, SSTR4, SSTR3 | MME 230/4885ACE 1320/4885CPA1 600/4885 |
| US-20230293736-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | MME 273/4885ACE 1555/4885CPA1 480/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | MME 339/4885ACE 118/4885CPA1 32/4885 |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | MME 273/4885ACE 1555/4885CPA1 480/4885 |
| US-20240181094-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | MME 273/4885ACE 1555/4885CPA1 480/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MME 776/4885ACE 836/4885CPA1 303/4885 |
| US-20240123098-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | MME 106/4885ACE 4209/4885CPA1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.